News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC
A publication in Nature Reviews Clinical Oncology highlights that datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, has demonstrated an overall survival benefit when used as first-line treatment in patients with advanced-stage triple-negative breast cancer (TNBC). Overall survival is the gold-standard endpoint in oncology trials, and achieving a statistically significant improvemen…
Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
A study published in the Journal of Clinical Oncology reports the development and validation of an artificial intelligence–powered computational histology biomarker designed to guide chemotherapy selection in patients with advanced pancreatic cancer. The tool analyzes standard pathology tissue slides using AI to predict which patients are most likely to benefit from specific chemotherapy regimens,…
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
A Phase III superiority randomized trial (DELII) published in the Journal of Clinical Oncology evaluated an ultra-low-dose immunotherapy regimen in patients with relapsed or refractory solid tumors, a population with severely limited treatment options. The study demonstrated that dramatically reduced doses of immunotherapy can achieve meaningful clinical benefit compared to control, potentially re…
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
The American Society of Clinical Oncology (ASCO) has published an updated clinical practice guideline on the use of immunotherapy and targeted therapy in advanced gastroesophageal cancer, appearing in the Journal of Clinical Oncology in April 2026. The update consolidates the latest evidence from pivotal trials to redefine recommended treatment sequences, biomarker-driven agent selection, and comb…
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
A phase III randomized noninferiority trial (neoCARHP), published in the Journal of Clinical Oncology, investigated whether carboplatin can be safely omitted from the neoadjuvant regimen of taxane plus trastuzumab and pertuzumab in patients with HER2-positive breast cancer. The trial addresses a critical clinical question about treatment de-escalation, aiming to reduce the well-known toxicity burd…
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603
The Journal of Clinical Oncology has published the long-term results of JCOG0603, a landmark Japanese randomized Phase II/III trial evaluating whether adding adjuvant mFOLFOX6 chemotherapy after liver resection improves outcomes for patients with colorectal cancer liver metastases compared to surgery alone. This trial addresses a longstanding clinical question, as the role of adjuvant chemotherapy…
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
The Journal of Clinical Oncology has published the HER2CLIMB-05 trial, a Phase III randomized study evaluating the addition of tucatinib to the standard first-line backbone of trastuzumab and pertuzumab as maintenance therapy in HER2-positive metastatic breast cancer. Tucatinib is a highly selective oral HER2-targeted tyrosine kinase inhibitor already approved for later-line HER2-positive disease …
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
The Prostate Cancer Working Group 4 (PCWG4) has published updated consensus recommendations for clinical trial design and endpoint selection in prostate cancer, appearing in the Journal of Clinical Oncology. Building on the widely adopted PCWG3 framework from 2016, the new guidelines reflect the rapidly evolving treatment landscape that now includes PARP inhibitors, radioligand therapies, and nove…
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
The Journal of Clinical Oncology has published full results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib, a pan-class I PI3K/mTOR dual inhibitor, combined with fulvestrant with or without palbociclib in patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring wild-type PIK3CA. This trial addresses a critical unmet need, as current PI3K-targeted agents suc…
[News] India introduces human papillomavirus vaccination
On February 28, 2026, Indian Prime Minister Narendra Modi launched the largest free human papillomavirus (HPV) vaccination campaign in history, aiming to immunize 11.5 million girls aged 14 across the country within 90 days. The vaccines will be administered free of charge at government-run health facilities, with the program subsequently integrated into India's Universal Immunisation Programme fo…